Company Profile
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
Latest News
Is the VanEck Pharmaceutical ETF or State Street Health Care ETF the Better Buy for Your Portfolio?
The 3.4% Income Play That Beats the Dogs of the Dow Strategy
Johnson & Johnson Is Becoming A Narrower Company Than You Bought
Merck (MRK) Could Be 4% Undervalued As LIPFENDRA Approval Tests Its Premium Valuation
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Website | https://www.merck.com |
| Audit Risk | 7 |
| Board Risk | 7 |
| Overall Risk | 3 |
| Market Cap | 323.72B |
| Trailing P/E | 36.92 |
| Forward P/E | 13.57 |
| Dividend Rate | 3.4 |
| Dividend Yield | 2.61% |
| Trailing Annual Div. Rate | 3.28 |
| Trailing Annual Div. Yield | 2.51% |
| Trailing EPS | 3.55 |
| Forward EPS | 9.66 |
| Book Value | 18.58 |
| Price-to-Book | 7.06 |
| Enterprise-to-Revenue | 5.58 |
| Enterprise-to-EBITDA | 12.44 |
| Short Ratio | 2.59 |
| Ex-Dividend Date | 06/15/2026 |
| Dividend Date | 07/08/2026 |
| Earnings Date | 08/04/2026 |
| Earnings Call Date | 08/04/2026 |
| Earnings Average | -0.26 |
| Earnings Low | -0.4 |
| Earnings High | -0.03 |
| Revenue Average | 16.37B |
| Revenue Low | 15.90B |
| Revenue High | 16.55B |